Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TB 403

Drug Profile

TB 403

Alternative Names: Anti-placental growth factor monoclonal antibody; Anti-PlGF; Anti-PlGF monoclonal antibody; R-7334; RG 7334; RO-5323441; TB-403; THR-317; αPlGF

Latest Information Update: 10 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioInvent International; ThromboGenics
  • Developer BioInvent International; Oncurious; Oxurion; Roche; ThromboGenics
  • Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Placenta growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Medulloblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Retinal telangiectasis
  • Phase I/II Medulloblastoma
  • No development reported Age-related macular degeneration; Glioblastoma; Liver cancer; Solid tumours

Most Recent Events

  • 20 Sep 2018 Oxurion initiates enrolment in a phase II trial for Retinal Telangiectasis in Switzerland (NCT03669393)
  • 20 Sep 2018 Phase-II clinical trials in Retinal telangiectasis (Intravitreous) in Switzerland (NCT03669393)
  • 13 Sep 2018 ThromboGenics plans the MacTel 1 phase II trial for Retinal-telangiectasis in September 2018 , (NCT03669393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top